The current state of health services highlights crucial sectors facing disruptions and developments, from US foreign aid freezes affecting disease control supply chains, to the FDA's actions on new ...

TD Cowen projects that with Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) continuing their dominance, global sales of the GLP-1 class of weight loss/obesity drugs could reach $139B by 2030, indicating ...

High-end brands are churning through creative directors as they try to revive sales.

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o ...

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration ...

The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

The U.S. Food and Drug Administration declared that the shortage of Novo Nordisk's weight-loss medications Wegovy and Ozempic has been resolved, according to its website. The FDA announcement confirms ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.